Basel Medical Group Ltd
BMGL
$0.61
$0.024.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,539.64% | -1,474.50% | -124.19% | -124.45% | -37.40% |
| Total Depreciation and Amortization | 227.62% | 213.02% | 34.08% | 35.61% | 10.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,437.47% | 4,242.06% | -253.14% | -254.75% | -221.24% |
| Change in Net Operating Assets | -189.66% | -185.60% | -123.75% | -126.22% | 1,804.87% |
| Cash from Operations | -111.17% | -110.66% | -2,767.54% | -2,796.81% | 52.95% |
| Capital Expenditure | -- | -- | -137.93% | -141.38% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 565.52% | 568.97% | 100.00% |
| Total Debt Issued | 964.41% | 964.41% | 866.42% | 866.42% | 110.38% |
| Total Debt Repaid | -213.71% | -213.71% | -247.35% | -247.35% | -118.03% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -787.33% | -787.33% | 1,382.48% | 1,382.48% | -239,950.00% |
| Cash from Financing | 654.87% | 629.77% | 2,387.03% | 2,412.18% | 22.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -554.84% | -534.30% | 2,130.64% | 2,153.00% | 588.45% |